Prevalence of iatrogenic hyperthyroidism in a community hospital

Journal of the American Board of Family Practice

Volumn 11, Issue 3, 1998, Pages 175-179

  Watsky, Jay G ^a,b   Koeniger, Mark A ^a  

^a Force Base   (Norway)

^b Endocrine Group   (United States)

Author keywords

Particularly for postmenopausal women and patients with heart disease; Public health concern

Indexed keywords

THYROTROPIN; THYROXINE;

ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL PRACTICE; COMMUNITY HOSPITAL; DRUG UTILIZATION; FEMALE; HUMAN; HYPERTHYROIDISM; IATROGENIC DISEASE; MALE; MIDDLE AGED;

DRUG UTILIZATION; FEMALE; HOSPITALS, COMMUNITY; HUMANS; HYPERTHYROIDISM; IATROGENIC DISEASE; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; THYROTROPIN; THYROXINE;

EID: 0032063164     PISSN: 08938652     EISSN: None     Source Type: Journal    
DOI: 10.3122/15572625-11-3-175     Document Type: Article

References (31)

1. Kaufman SC, Gross TP, Kennedy DL. Thyroid hormone use: trends in the United States from 1960 through 1988. Thyroid 1991;1:285-91.
2. Petersen K, Bengtsson C, Lapidus L, Lindstedt G, Nystrom E. Morbidity, mortality, and quality of life for patients treated with levothyroxine. Arch Intern Med 1990;150:2077-81.
3. Burman KD. Is long-term levothyroxine therapy safe? Arch Intern Med 1990;150:2010-3.
4. Fallon MD, Perry HM 3d, Bergfeld M, Droke D, Teitelbaum SL, Avioli LV. Exogenous hyperthyroidism with osteoporosis. Arch Intern Med 1983; 143:442-4.
5. Marcocci C, Golia F, Bruno-Bossio G, Vignali E, Pinchera A. Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women. J Clin Endocrinol Metab 1994;78:818-23.
6. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol 1994;130:350-6.
7. Ross DS, Neer RM, Ridgway EC, Daniels GH. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med 1987; 82:1167-70.
8. Paul TL, Kerrigan J, Kelly AM, Braverman LE, Baran DT. Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women. JAMA 1988;259:3137-41.
9. Ross DS. Subclinical hyperthyroidism: possible danger of overzealous thyroxine replacement therapy. Mayo Clin Proc 1988;63:1223-9.
10. Stall GM, Harris S, Sokoll LJ, Dawson-Hughes B. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. Ann Intern A led 1990; 113:265-9.
11. Diamond T, Nery L, Hales I. A therapeutic dilemma: suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab 1991;72:1184-8.
12. Adlin EV, Maurer AH, Marks AD, Channick BJ. Bone mineral density in postmenopausal women treated with L-thyroxine. Am J Med 1991;90:360-6.
13. Leese GP, Jung RT, Gudirie C, Waugh N, Browning MC. Morbidity in patients on 1-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH. Clin Endocrinol Oxf 1992;37:500-3.
14. Solomon BL, Wartofsky L, Burman KD. Prevalence of fractures in postmenopausal women with thyroid disease. Thyroid 1993;3:17-23.
15. Bauer DC, Cummings SR, Tao JL, Browner WS. Hyperthyroidism increases the risk of hip fractures: a prospective study. J Bone Miner Res 1992;7(Suppl 1):121.
16. Kanis JA. Osteoporosis. Cambridge, Mass: Blackwell Scientific, 1994:1-20.
17. Consensus Development Conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94:646-50.
18. Biondi B, Fazio S, Carella C, Amato G, Cittadini A, Lupoli G, et al. Cardiac effects of long-term thyrotropin suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1993;77:334-8.
19. Forfar JC, Miller HC, Toft AD. Occult thyrotoxicosis: a correctable cause of "ideopathic" atrial fibrillation. Am J Cardiol 1979;44:9-12.
20. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331:1249-52.
21. Ladenson PW. Thyrotoxicosis and the heart: something old and something new. J Clin Endocrinol Metab 1993;77:332-3.
22. Levy D, Garrison RJ, Savage DD, Kannel WB. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6.
23. Figge J, Leinung M, Goodman AD, Izquierdo R, Mydosh T, Gates S, et al. The clinical evaluation of patients with subclinical hyperthyroidism and free triiodothyronine (free T3) toxicosis. Am J Med 1994; 96:229-34.
24. Toft AD. Thyroxine therapy. N Engl J Med 1994; 331:174-80.
25. Kaplan MM. Thyroid hormone therapy, what, when, and how much. Postgrad Med 1993;193:249-52, 255-6, 260-2.
26. Burmeister LA. Thyroid hormone in the treatment of thyroid cancer. Thyroid Today 1994;17(1):1-9.
27. Cooper D. Thyroxine suppressive therapy for benign nodular disease. J Clin Endocrinol Metab 1995;80: 331-4.
28. Mandel SJ, Brent GA, Larsen PR. Levothyroxine therapy in patients with thyroid disease. Ann Intern Med 1993;119:492-502.
29. Wartofsky L. Use of sensitive TSH assay to determine optimal thyroid hormone therapy and avoid osteoporosis. Ann Rev Med 1991;42:341-5.
30. Hamburger JI, Kaplan MM. Hypothyroidism. Don't treat patients who don't have it. Postgrad Med 1989; 86:67-74.
31. Cooper DS, Halpern R, Wood LC, Levin AA, Ridgway EC. L-Thyroxine therapy in subclinical hypothyroidism. A double-blind, placebo-controlled trial. Ann Intern Med 1984;101:18-24.